| Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention
of menstrual migraine.The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe. The aim
of the present study was to develop buccal formulation of Frovatriptan to maintain constant therapeutic levels of the drug
for over 12 hrs. HPMCK4M, HPMCK15M and Locust bean gum were employed as polymers. Frovatriptan dose was
fixed as 2.5 mg. Total weight of the tablet was considered as 60 mg. Polymers were used in the concentration of 5 mg, 10
mg and 15 mg concentration. All the formulations were passed various physicochemical evaluation parameters and they
were found to be within limits. Whereas from the dissolution studies it was evident that the formulation (F3) showed better
and desired drug release pattern i.e.,98.03 % in 12 hours. It followed zero order release kinetics mechanismddd |
